SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '4E1'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1FMO_E_ADNE351_1 (CAMP-DEPENDENT PROTEIN KINASE)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	7 / 12	GLY A 166 VAL A 173 ALA A 186 VAL A 222 ASN A 292 LEU A 294 ASP A 307	4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None None None 4E1 A 505 (-3.6A)	0.73A	1fmoE-4yljA: 25.6	1fmoE-4yljA: 26.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWH_A_BAXA1723_2 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 6	ILE A 165 VAL A 173 ILE A 221 ILE A 283	4E1 A 505 ( 4.6A) 4E1 A 505 (-4.5A) None None	0.62A	1uwhA-4yljA: 20.9	1uwhA-4yljA: 27.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1UWJ_A_BAXA1723_2 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 7	ILE A 165 LYS A 188 LEU A 207 ILE A 221 ILE A 283	4E1 A 505 ( 4.6A) 4E1 A 505 (-2.7A) None None None	0.64A	1uwjA-4yljA: 6.5	1uwjA-4yljA: 27.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EUF_B_LQQB401_1 (CELL DIVISION PROTEIN KINASE 6)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	8 / 12	ILE A 165 VAL A 173 LYS A 188 VAL A 222 PHE A 238 ASN A 292 LEU A 294 ASP A 307	4E1 A 505 ( 4.6A) 4E1 A 505 (-4.5A) 4E1 A 505 (-2.7A) None 4E1 A 505 (-4.2A) None None 4E1 A 505 (-3.6A)	0.69A	2eufB-4yljA: 30.7	2eufB-4yljA: 29.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3LFA_A_1N1A361_1 (MITOGEN-ACTIVATED PROTEIN KINASE 14)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 8	ALA A 186 LYS A 188 GLU A 203 LEU A 236	4E1 A 505 (-3.5A) 4E1 A 505 (-2.7A) None None	0.38A	3lfaA-4yljA: 24.7	3lfaA-4yljA: 27.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3RGF_A_BAXA465_1 (CYCLIN-DEPENDENT KINASE 8)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	7 / 12	VAL A 173 ALA A 186 GLU A 203 LEU A 207 PHE A 238 LEU A 276 HIS A 285	4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None None 4E1 A 505 (-4.2A) None None	0.71A	3rgfA-4yljA: 9.1	3rgfA-4yljA: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3WAR_A_NIOA401_1 (CASEIN KINASE II SUBUNIT ALPHA)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 8	VAL A 173 LYS A 188 PHE A 238 ASP A 307	4E1 A 505 (-4.5A) 4E1 A 505 (-2.7A) 4E1 A 505 (-4.2A) 4E1 A 505 (-3.6A)	0.44A	3warA-4yljA: 29.4	3warA-4yljA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IAA_A_RTZA401_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	6 / 11	VAL A 173 ALA A 186 LYS A 188 GLU A 291 LEU A 294 ASP A 307	4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) 4E1 A 505 (-2.7A) None None 4E1 A 505 (-3.6A)	0.99A	4iaaA-4yljA: 24.7	4iaaA-4yljA: 23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IFG_A_1E8A601_1 (CALMODULIN-DOMAIN PROTEIN KINASE 1)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	6 / 12	GLY A 166 VAL A 173 ALA A 186 LEU A 224 LEU A 236 LEU A 294	4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None None None	0.39A	4ifgA-4yljA: 21.6	4ifgA-4yljA: 25.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_A_ADNA401_1 (CYCLIN-DEPENDENT KINASE 9)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 8	ILE A 165 VAL A 173 ALA A 186 ASN A 292 LEU A 294	4E1 A 505 ( 4.6A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None None	0.54A	4ogrA-4yljA: 29.9	4ogrA-4yljA: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_A_ADNA401_1 (CYCLIN-DEPENDENT KINASE 9)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 8	ILE A 165 VAL A 173 ASN A 292 LEU A 294 ASP A 307	4E1 A 505 ( 4.6A) 4E1 A 505 (-4.5A) None None 4E1 A 505 (-3.6A)	0.60A	4ogrA-4yljA: 29.9	4ogrA-4yljA: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OGR_I_ADNI401_1 (CYCLIN-DEPENDENT KINASE 9)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	6 / 9	ILE A 165 VAL A 173 ALA A 186 ASN A 292 LEU A 294 ASP A 307	4E1 A 505 ( 4.6A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None None 4E1 A 505 (-3.6A)	0.68A	4ogrI-4yljA: 29.7	4ogrI-4yljA: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4OTI_A_MI1A1001_1 (SERINE/THREONINE-PRO TEIN KINASE N1)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	7 / 12	GLY A 166 GLY A 168 GLY A 171 VAL A 173 ALA A 186 LYS A 188 LEU A 294	4E1 A 505 (-3.5A) 4E1 A 505 ( 4.9A) None 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) 4E1 A 505 (-2.7A) None	0.55A	4otiA-4yljA: 20.3	4otiA-4yljA: 25.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 12	ALA A 186 LYS A 188 LEU A 207 ASP A 307 PHE A 308	4E1 A 505 (-3.5A) 4E1 A 505 (-2.7A) None 4E1 A 505 (-3.6A) None	0.80A	4xv2B-4yljA: 21.3	4xv2B-4yljA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 12	VAL A 173 ALA A 186 LYS A 188 LEU A 207 PHE A 308	4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) 4E1 A 505 (-2.7A) None None	0.71A	5cswA-4yljA: 20.6	5cswA-4yljA: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 12	VAL A 173 ALA A 186 LYS A 188 LEU A 207 PHE A 308	4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) 4E1 A 505 (-2.7A) None None	0.70A	5cswB-4yljA: 20.6	5cswB-4yljA: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_F_AZ1F2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR-DAR)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 7	GLY A 166 GLY A 168 SER A 169 GLY A 171 VAL A 173	4E1 A 505 (-3.5A) 4E1 A 505 ( 4.9A) None None 4E1 A 505 (-4.5A)	0.61A	5izjB-4yljA: 24.5	5izjB-4yljA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5IZJ_G_AZ1G2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAR-DAR)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 7	GLY A 166 GLY A 168 SER A 169 VAL A 173	4E1 A 505 (-3.5A) 4E1 A 505 ( 4.9A) None 4E1 A 505 (-4.5A)	0.41A	5izjA-4yljA: 24.9	5izjA-4yljA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5J5X_B_AZ1B2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAL-DAR-DAR- DAR-DAR)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	5 / 7	GLY A 166 GLY A 168 SER A 169 VAL A 173 LYS A 188	4E1 A 505 (-3.5A) 4E1 A 505 ( 4.9A) None 4E1 A 505 (-4.5A) 4E1 A 505 (-2.7A)	0.55A	5j5xA-4yljA: 25.2	5j5xA-4yljA: 25.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2I_A_LQQA900_1 (CYCLIN-DEPENDENT KINASE 6)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	7 / 12	ILE A 165 GLY A 166 VAL A 173 ALA A 186 VAL A 222 PHE A 238 LEU A 294	4E1 A 505 ( 4.6A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None 4E1 A 505 (-4.2A) None	0.74A	5l2iA-4yljA: 12.8	5l2iA-4yljA: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	6 / 12	ILE A 165 GLY A 166 VAL A 173 ALA A 186 PHE A 238 LEU A 294	4E1 A 505 ( 4.6A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.2A) None	0.83A	5l2tA-4yljA: 12.8	5l2tA-4yljA: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L2T_A_6ZZA900_1 (CYCLIN-DEPENDENT KINASE 6)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	6 / 12	ILE A 165 GLY A 166 VAL A 173 ALA A 186 VAL A 222 PHE A 238	4E1 A 505 ( 4.6A) 4E1 A 505 (-3.5A) 4E1 A 505 (-4.5A) 4E1 A 505 (-3.5A) None 4E1 A 505 (-4.2A)	0.88A	5l2tA-4yljA: 12.8	5l2tA-4yljA: 29.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5OWR_A_1N1A401_1 (SERINE/THREONINE-PRO TEIN KINASE 10)	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 8	ALA A 186 GLU A 203 LEU A 294 ASP A 307	4E1 A 505 (-3.5A) None None 4E1 A 505 (-3.6A)	0.51A	5owrA-4yljA: 21.3	5owrA-4yljA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y9M_X_NIOX401_1 (CASEIN KINASE II SUBUNIT ALPHA')	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 8	VAL A 173 LYS A 188 PHE A 238 ASP A 307	4E1 A 505 (-4.5A) 4E1 A 505 (-2.7A) 4E1 A 505 (-4.2A) 4E1 A 505 (-3.6A)	0.28A	5y9mX-4yljA: 28.1	5y9mX-4yljA: 11.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YF9_B_NIOB401_1 (CASEIN KINASE II SUBUNIT ALPHA')	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 7	VAL A 173 LYS A 188 PHE A 238 ASP A 307	4E1 A 505 (-4.5A) 4E1 A 505 (-2.7A) 4E1 A 505 (-4.2A) 4E1 A 505 (-3.6A)	0.50A	5yf9B-4yljA: 28.0	5yf9B-4yljA: 11.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YWM_X_NIOX403_0 (CASEIN KINASE II SUBUNIT ALPHA')	4ylj	DUAL SPECIFICITY TYROSINE-PHOSPHORYLA TION-REGULATED KINASE 1A (Homo sapiens)	4 / 7	VAL A 173 LYS A 188 PHE A 238 ASP A 307	4E1 A 505 (-4.5A) 4E1 A 505 (-2.7A) 4E1 A 505 (-4.2A) 4E1 A 505 (-3.6A)	0.38A	5ywmX-4yljA: 28.1	5ywmX-4yljA: 11.11

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1FMO_E_ADNE351_1","CAMP-DEPENDENT PROTEIN KINASE","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",7,"GLY A 166;VAL A 173;ALA A 186;VAL A 222;ASN A 292;LEU A 294;ASP A 307","4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;None;None;4E1 A 505 (-3.6A)","0.73A","1fmoE-4yljA:25.6",null],["1UWH_A_BAXA1723_2","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"ILE A 165;VAL A 173;ILE A 221;ILE A 283","4E1 A 505 ( 4.6A);4E1 A 505 (-4.5A);None;None","0.62A","1uwhA-4yljA:20.9","1fmoE-4yljA:26.08"],["1UWJ_A_BAXA1723_2","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"ILE A 165;LYS A 188;LEU A 207;ILE A 221;ILE A 283","4E1 A 505 ( 4.6A);4E1 A 505 (-2.7A);None;None;None","0.64A","1uwjA-4yljA:6.5","1uwhA-4yljA:27.25"],["2EUF_B_LQQB401_1","CELL DIVISION PROTEIN KINASE 6","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",8,"ILE A 165;VAL A 173;LYS A 188;VAL A 222;PHE A 238;ASN A 292;LEU A 294;ASP A 307","4E1 A 505 ( 4.6A);4E1 A 505 (-4.5A);4E1 A 505 (-2.7A);None;4E1 A 505 (-4.2A);None;None;4E1 A 505 (-3.6A)","0.69A","2eufB-4yljA:30.7","1uwjA-4yljA:27.25"],["3LFA_A_1N1A361_1","MITOGEN-ACTIVATED PROTEIN KINASE 14","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"ALA A 186;LYS A 188;GLU A 203;LEU A 236","4E1 A 505 (-3.5A);4E1 A 505 (-2.7A);None;None","0.38A","3lfaA-4yljA:24.7","2eufB-4yljA:29.29"],["3RGF_A_BAXA465_1","CYCLIN-DEPENDENT KINASE 8","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",7,"VAL A 173;ALA A 186;GLU A 203;LEU A 207;PHE A 238;LEU A 276;HIS A 285","4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;None;4E1 A 505 (-4.2A);None;None","0.71A","3rgfA-4yljA:9.1","3lfaA-4yljA:27.72"],["3WAR_A_NIOA401_1","CASEIN KINASE II SUBUNIT ALPHA","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"VAL A 173;LYS A 188;PHE A 238;ASP A 307","4E1 A 505 (-4.5A);4E1 A 505 (-2.7A);4E1 A 505 (-4.2A);4E1 A 505 (-3.6A)","0.44A","3warA-4yljA:29.4","3rgfA-4yljA:27.27"],["4IAA_A_RTZA401_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",6,"VAL A 173;ALA A 186;LYS A 188;GLU A 291;LEU A 294;ASP A 307","4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);4E1 A 505 (-2.7A);None;None;4E1 A 505 (-3.6A)","0.99A","4iaaA-4yljA:24.7","3warA-4yljA:28.57"],["4IFG_A_1E8A601_1","CALMODULIN-DOMAIN PROTEIN KINASE 1","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",6,"GLY A 166;VAL A 173;ALA A 186;LEU A 224;LEU A 236;LEU A 294","4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;None;None","0.39A","4ifgA-4yljA:21.6","4iaaA-4yljA:23.53"],["4OGR_A_ADNA401_1","CYCLIN-DEPENDENT KINASE 9","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"ILE A 165;VAL A 173;ALA A 186;ASN A 292;LEU A 294","4E1 A 505 ( 4.6A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;None","0.54A","4ogrA-4yljA:29.9","4ifgA-4yljA:25.45"],["4OGR_A_ADNA401_1","CYCLIN-DEPENDENT KINASE 9","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"ILE A 165;VAL A 173;ASN A 292;LEU A 294;ASP A 307","4E1 A 505 ( 4.6A);4E1 A 505 (-4.5A);None;None;4E1 A 505 (-3.6A)","0.60A","4ogrA-4yljA:29.9","4ogrA-4yljA:27.01"],["4OGR_I_ADNI401_1","CYCLIN-DEPENDENT KINASE 9","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",6,"ILE A 165;VAL A 173;ALA A 186;ASN A 292;LEU A 294;ASP A 307","4E1 A 505 ( 4.6A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;None;4E1 A 505 (-3.6A)","0.68A","4ogrI-4yljA:29.7","4ogrA-4yljA:27.01"],["4OTI_A_MI1A1001_1","SERINE\/THREONINE-PROTEIN KINASE N1","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",7,"GLY A 166;GLY A 168;GLY A 171;VAL A 173;ALA A 186;LYS A 188;LEU A 294","4E1 A 505 (-3.5A);4E1 A 505 ( 4.9A);None;4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);4E1 A 505 (-2.7A);None","0.55A","4otiA-4yljA:20.3","4ogrI-4yljA:27.01"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"ALA A 186;LYS A 188;LEU A 207;ASP A 307;PHE A 308","4E1 A 505 (-3.5A);4E1 A 505 (-2.7A);None;4E1 A 505 (-3.6A);None","0.80A","4xv2B-4yljA:21.3","4otiA-4yljA:25.99"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"VAL A 173;ALA A 186;LYS A 188;LEU A 207;PHE A 308","4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);4E1 A 505 (-2.7A);None;None","0.71A","5cswA-4yljA:20.6","4xv2B-4yljA:28.57"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"VAL A 173;ALA A 186;LYS A 188;LEU A 207;PHE A 308","4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);4E1 A 505 (-2.7A);None;None","0.70A","5cswB-4yljA:20.6","5cswA-4yljA:28.19"],["5IZJ_F_AZ1F2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR-DAR","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"GLY A 166;GLY A 168;SER A 169;GLY A 171;VAL A 173","4E1 A 505 (-3.5A);4E1 A 505 ( 4.9A);None;None;4E1 A 505 (-4.5A)","0.61A","5izjB-4yljA:24.5","5cswB-4yljA:28.19"],["5IZJ_G_AZ1G2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAR-DAR","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"GLY A 166;GLY A 168;SER A 169;VAL A 173","4E1 A 505 (-3.5A);4E1 A 505 ( 4.9A);None;4E1 A 505 (-4.5A)","0.41A","5izjA-4yljA:24.9","5izjB-4yljA:25.07"],["5J5X_B_AZ1B2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAL-DAR-DAR-DAR-DAR","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",5,"GLY A 166;GLY A 168;SER A 169;VAL A 173;LYS A 188","4E1 A 505 (-3.5A);4E1 A 505 ( 4.9A);None;4E1 A 505 (-4.5A);4E1 A 505 (-2.7A)","0.55A","5j5xA-4yljA:25.2","5izjA-4yljA:25.07"],["5L2I_A_LQQA900_1","CYCLIN-DEPENDENT KINASE 6","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",7,"ILE A 165;GLY A 166;VAL A 173;ALA A 186;VAL A 222;PHE A 238;LEU A 294","4E1 A 505 ( 4.6A);4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;4E1 A 505 (-4.2A);None","0.74A","5l2iA-4yljA:12.8","5j5xA-4yljA:25.07"],["5L2T_A_6ZZA900_1","CYCLIN-DEPENDENT KINASE 6","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",6,"ILE A 165;GLY A 166;VAL A 173;ALA A 186;PHE A 238;LEU A 294","4E1 A 505 ( 4.6A);4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);4E1 A 505 (-4.2A);None","0.83A","5l2tA-4yljA:12.8","5l2iA-4yljA:29.18"],["5L2T_A_6ZZA900_1","CYCLIN-DEPENDENT KINASE 6","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",6,"ILE A 165;GLY A 166;VAL A 173;ALA A 186;VAL A 222;PHE A 238","4E1 A 505 ( 4.6A);4E1 A 505 (-3.5A);4E1 A 505 (-4.5A);4E1 A 505 (-3.5A);None;4E1 A 505 (-4.2A)","0.88A","5l2tA-4yljA:12.8","5l2tA-4yljA:29.18"],["5OWR_A_1N1A401_1","SERINE\/THREONINE-PROTEIN KINASE 10","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"ALA A 186;GLU A 203;LEU A 294;ASP A 307","4E1 A 505 (-3.5A);None;None;4E1 A 505 (-3.6A)","0.51A","5owrA-4yljA:21.3","5l2tA-4yljA:29.18"],["5Y9M_X_NIOX401_1","CASEIN KINASE II SUBUNIT ALPHA'","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"VAL A 173;LYS A 188;PHE A 238;ASP A 307","4E1 A 505 (-4.5A);4E1 A 505 (-2.7A);4E1 A 505 (-4.2A);4E1 A 505 (-3.6A)","0.28A","5y9mX-4yljA:28.1","5owrA-4yljA:28.53"],["5YF9_B_NIOB401_1","CASEIN KINASE II SUBUNIT ALPHA'","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"VAL A 173;LYS A 188;PHE A 238;ASP A 307","4E1 A 505 (-4.5A);4E1 A 505 (-2.7A);4E1 A 505 (-4.2A);4E1 A 505 (-3.6A)","0.50A","5yf9B-4yljA:28.0","5y9mX-4yljA:11.11"],["5YWM_X_NIOX403_0","CASEIN KINASE II SUBUNIT ALPHA'","4ylj","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","Homo sapiens",4,"VAL A 173;LYS A 188;PHE A 238;ASP A 307","4E1 A 505 (-4.5A);4E1 A 505 (-2.7A);4E1 A 505 (-4.2A);4E1 A 505 (-3.6A)","0.38A","5ywmX-4yljA:28.1","5yf9B-4yljA:11.11"]]